cancer immunotherapy– tag –

Series finale. Same metastatic RCC, contrasting designs: PERFORM (healthy donor, ipi/nivo) vs TACITO (ICI complete-responder donor, pembro+axitinib). The cross-trial Segatella copri context-dependent toxicity discovery (drives toxicity ONLY under dual ICI), the three-layer commercial map (Seres/Vedanta/Exeliom; Locus/Eligo; rational consortia), and structural implications for the global ecosystem. The clinical-translation year of FMT/LBP, synthesized.

Building on Volume 1, we dissect the convergent finding across the three April 2026 Nature Medicine trials: FMT works because patients lose their own deleterious bacteria, not because they acquire donor bacteria. FMT-LUMINate's mouse reverse-experiment proved causality. Mechanism: tryptophan/kynurenine pathway disturbance, IDO/AhR axis, regulatory T-cell expansion. Vol. 2 of the series.

In April 2026, Nature Medicine Vol. 32 No. 4 published three FMT-plus-immunotherapy trials in a single issue: 80% ORR in NSCLC, and a doubling of progression-free survival in metastatic RCC (24.0 vs 9.0 months, HR 0.50). But the deeper significance lies not in the numbers — it is the shared mechanistic finding that responders selectively lost their own deleterious bacteria, rather than acquiring beneficial bacteria from the donor. Volume 1 of our series surveys all three trials and what their simultaneous publication means.

Strategic Review: Shifting from Antivirals to Oncology and Cell Therapy Gilead Sciences, once dominant in the antiviral space—particularly in HIV and hepatitis C—has been facing declining revenue due to patent cliffs. Gilead Sciences, on...

Strategic Review: Diversifying Beyond Humira AbbVie has proactively diversified its portfolio beyond Humira, expanding into oncology, neuroscience, immunology, ophthalmology, and aesthetics. Its acquisition of Allergan, ADC platforms, an...